2024
- What is the recommended duration of naltrexone treatment for alcohol use disorder?
- What literature is available on how pharmacy can play a role in reducing health care’s climate footprint?
- What heparin dosing regimens should be used for indications related to peripheral artery disease?
- What information is available to guide the practice of therapeutic drug monitoring for itraconazole, posaconazole, voriconazole, and isavuconazonium sulfate?
- What are the latest updates and guideline recommendations in MASLD/MASH?
- What are the current treatment recommendations for Mpox infections?
- Update: Does the literature support the use of doxycycline for post-exposure prophylaxis against sexually transmitted infections?
- Update: What is the role for commercially available fecal microbiota transplantation products in managing recurrent Clostridioides difficile infection?
- Are there data to support dose intensification of golimumab for moderate to severe inflammatory bowel disease (e.g., 100 mg every 2 weeks)?
- What evidence supports the efficacy and safety of donanemab for Alzheimer disease?
- Is methylene blue a recommended non-catecholamine vasopressor to treat vasodilatory shock?
- What is the comparative safety of IV bisphosphonates for the treatment of hypercalcemia in patients with renal dysfunction?
- What is the recommended dosage of anakinra (Kineret) for secondary hemophagocytic lymphohistiocytosis (HLH)?
- Are the sodium-glucose cotransporter-2 (SGLT2) inhibitors effective for reducing contrast-associated acute kidney injury?
- What literature is available on oral beta-lactam therapy for gram-negative bacteremia?
- What efficacy supports the use of liposomal bupivacaine for post-cesarean pain control?
- What are the current recommendations for administration of live vaccines in patients receiving dupilumab?
- What information is available on the newly approved Moderna RSV vaccine (mRESVIA®) and how does it compare with other currently available RSV vaccines?
- What are the features of calculators used to estimated cardiovascular disease risk?
- What is tianeptine, and are there recommendations for managing tianeptine misuse/withdrawal in the medical setting?
- What are current recommendations on travel vaccine administration?
- What literature is available on GLP-1 receptor agonists in the setting of bariatric surgery?
- What are the differences in efficacy and safety of intranasal naloxone versus nalmefene?
- What new evidence is available regarding intravenous iron replacement in patients with heart failure?
- How do brexanolone and zuranolone compare in patients with postpartum depression?
- Is intravenous hydroxocobalamin an effective treatment for vasoplegia-associated shock?
- What information is available on vaccines for the prevention of RSV?
- What are the Available and Emerging Phosphodiesterase 4 Inhibitors for COPD Treatment?
- What are key pharmacologic recommendations in the management type 2 diabetes based on updated 2023 American Association of Clinical Endocrinologists (AACE) type 2 diabetes algorithm and 2024 American Diabetes Association (ADA) guidelines?
- What information is available on gene therapies for treatment of beta-thalassemia?
- Are there any guidelines supporting the use of metered dose inhalers (MDIs) versus nebulizers regarding infection transmission?
- What information is available on novel gene therapies for treatment of sickle cell disease?
- What is the role of colchicine in reducing the risk of cardiovascular events in adults?
- What information is available on the off-label use of gabapentin and topiramate for alcohol use disorder?
- What evidence supports the use of azithromycin for ruptured membranes in preterm prelabor?
- Does the available evidence support the use of anakinra in the management of constrictive pericarditis?